Cibc World Market Inc. Buys Shares of 279,932 Genmab A/S Sponsored ADR $GMAB

Cibc World Market Inc. bought a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 279,932 shares of the company’s stock, valued at approximately $8,586,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Osaic Holdings Inc. lifted its stake in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after acquiring an additional 440 shares during the last quarter. CWM LLC increased its stake in Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after purchasing an additional 603 shares during the period. AlphaCore Capital LLC purchased a new stake in Genmab A/S in the second quarter worth $44,000. EverSource Wealth Advisors LLC boosted its stake in shares of Genmab A/S by 124.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after purchasing an additional 1,174 shares during the period. Finally, Cromwell Holdings LLC grew its holdings in shares of Genmab A/S by 136.3% in the third quarter. Cromwell Holdings LLC now owns 1,531 shares of the company’s stock worth $47,000 after purchasing an additional 883 shares during the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on GMAB. HC Wainwright reiterated a “buy” rating and set a $39.00 price objective on shares of Genmab A/S in a report on Wednesday, January 28th. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Truist Financial reaffirmed a “buy” rating and set a $48.00 price target (down previously from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Wall Street Zen cut Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Finally, Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.33.

Genmab A/S Trading Up 1.5%

Shares of NASDAQ GMAB opened at $30.03 on Friday. Genmab A/S Sponsored ADR has a 12-month low of $17.24 and a 12-month high of $35.43. The stock’s fifty day simple moving average is $32.35 and its two-hundred day simple moving average is $29.66. The stock has a market capitalization of $19.29 billion, a PE ratio of 12.78, a price-to-earnings-growth ratio of 17.37 and a beta of 0.90.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.